Potential for use sunitinib in pancreatic neuroendocrine tumors

The treatment efficacy and toxicity profile was evaluated in 33 patients with highly differentiated neuroendocrine tumors NEO (G1, G2), who received sunitinib therapy in various dose regimens. Stable disease was achieved in 24 patients (72.7%), partial effect in 1 patient (3%). The efficacy of treat...

詳細記述

書誌詳細

出版年:	Медицинский совет
主要な著者:	A. A. Markovich, A. A. Kuznetsova, V. A. Gorbunova, N. F. Orel, A. S. Odintsova, G. S. Emelyanova, A. E. Kuzminov
フォーマット:	論文
言語:	ロシア語
出版事項:	Remedium Group LLC 2019-06-01
主題:	neuroendocrine tumors sunitinib safety profile
オンライン･アクセス:	https://www.med-sovet.pro/jour/article/view/3061